# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Srikripa Devarakonda maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from ...
HC Wainwright & Co. analyst Sean Lee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $17.5 ...
RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $16 to...
Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.95) by 3...
Expect to report updated data from the ongoing RAMP 205 trial in first-line metastatic pancreatic cancer in Q1 2025Verastem Onc...
Verastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, to...